饮食在帕金森病中的作用
Kira N Tosefsky1,2, Julie Zhu2, Yolanda N Wang1
1Pacific Parkinson's Research Centre, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC, Canada.
Journal of Parkinson's disease
|January 22, 2024
概括
这篇评论探讨了营养的营养.
科学领域:
- 神经科学是一个神经科学.
- 营养科学 营养科学
- 流行病学 流行病学
背景情况:
- 帕金森病 (PD) 具有复杂的病因,越来越多的证据将营养与风险和进展联系起来.
- 虽然流行病学研究将饮食与PD风险联系起来,但较少的人评估了用于建立PD管理的饮食干预措施.
- 对饮食在帕金森病的症状管理和潜在疾病修饰中的作用有很大的兴趣.
研究的目的:
- 审查营养和帕金森病 (PD) 的交叉点.
- 为了确定PD管理的基于证据的营养实践.
- 突出证据缺口,并建议未来的PD营养研究方向.
主要方法:
- 对有关饮食和帕金森病的现有文献进行系统审查.
- 评估各种饮食模式:地中海 (MeDi),MIND,AHEI,素食主义者/素食主义者和性饮食.
- 关于PD风险,症状和进展的个人食品组和补充剂的证据概述.
主要成果:
- 流行病学研究表明,饮食模式/食物组与PD风险之间存在联系.
- 有限的研究评估特定的饮食,成分或补充剂来管理已建立的PD.
- 目前有证据表明饮食在症状管理和潜在疾病修饰中的作用.
结论:
- 营养干预措施对帕金森病 (PD) 管理有希望.
- 需要进一步的研究来确定PD的最佳饮食策略.
- 饮食模式和补充剂需要对PD的症状控制和疾病修饰进行调查.
相关概念视频
Parkinson's Disease: Treatment
272
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
272
Parkinson's Disease: Overview
551
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
551
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195


